The data from the CDC's National Immunization Survey estimates that 37.6% of Americans ages 65 and older had gotten a shot of ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

“a better dengue vaccine” While the DOH has avoided or chose not to post statistics on monthly active cases of dengue and dengue-related mortality, they have recently advised the public to be vigilant ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 ...

Moderna’s COVID-19 vaccine will soon have a figurative “made in North Carolina” stamp. Thermo Fisher Scientific, a contract manufacturer of pharmaceuticals, will begin making “hundreds of millions of ...

The Population and Vital Statistics Report presents most recent data on population size (total, male and female) from the latest available census of the population, national official population ...

Healthcare is possibly the most overlooked of all the mega-trends. But this may leave investors with more opportunities once ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...